Due to microbiological contamination at the Dutch biotech firm’s South Korean vaccine plant, WHO was forced to halt the shipments from the facility in October 2010.
After reviewing corrective steps taken by Crucell, WHO said that the problems identified in 2010 had been resolved.
In a statement, the WHO said it is confident that Crucell is operating according to good manufacturing practices.
"WHO will accept new batches of Quinvaxem produced by Crucell for supply through United Nations agencies," WHO said.
The release of newly produced batches of Quinvaxem is expected to resume this month